Last reviewed · How we verify
fosnetupitant/ palonosetron
Fosnetupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist that together prevent chemotherapy-induced nausea and vomiting (CINV) by blocking two distinct pathways in the chemoreceptor trigger zone and gastrointestinal tract.
Fosnetupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist that together prevent chemotherapy-induced nausea and vomiting (CINV) by blocking two distinct pathways in the chemoreceptor trigger zone and gastrointestinal tract. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.
At a glance
| Generic name | fosnetupitant/ palonosetron |
|---|---|
| Also known as | IV NEPA FDC |
| Sponsor | Helsinn Healthcare SA |
| Drug class | NK1 receptor antagonist / 5-HT3 receptor antagonist combination |
| Target | NK1 receptor (substance P receptor) / 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Fosnetupitant blocks neurokinin-1 (NK1) receptors, which are involved in the delayed phase of CINV, while palonosetron blocks serotonin 5-HT3 receptors, which mediate the acute phase of CINV. This dual-mechanism combination provides enhanced antiemetic coverage across both acute and delayed phases of chemotherapy-induced nausea and vomiting.
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Fatigue
- Diarrhea
Key clinical trials
- Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) (PHASE2)
- A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers (PHASE1)
- A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fosnetupitant/ palonosetron CI brief — competitive landscape report
- fosnetupitant/ palonosetron updates RSS · CI watch RSS
- Helsinn Healthcare SA portfolio CI